CAS:93479-97-1Glimepiride

您的位置 : 首页 / Membrane Transporter/Ion Channel / Potassium Channel / Glimepiride

Glimepiride 格列美脲 Cat No. FB00577Cas No. 93479-97-1

Glimepiride is a sulfonylurea which inhibit KATP with IC50 of 3.0 nM in pancreatic β-cells with fewer cardiac actions. It is used in the treatment of type 2 diabetes mellitus.

规格	价格	促销价格	库存

18817579266

立即询价

咨询

18817579266

立即询价

实验数据

储存液制备
- 1 mg
- 5 mg
- 10 mg
- 1 mM
- 2.0383 mL
- 10.1913 mL
- 20.3826 mL
- 5 mM
- 0.4077 mL
- 2.0383 mL
- 4.0765 mL
- 10 mM
- 0.2038 mL
- 1.0191 mL
- 2.0383 mL
计算器摩尔计算器总药量计算器工作液计算器

技术信息

CAS号

93479-97-1

储存条件

粉末: -20°C 3 年

液体: -80°C 12 月

分子式

C24H34N4O5S

运输

蓝冰

分子量

490.62

别名

溶解度

DMSO	15.0 mg/mL (30.6 mM)

动物实验配方

靶点数据

生物活性

描述Glimepiride (Hoe 490) is a new sulfonylurea. After oral administration of Hoe 490 to rabbits, blood glucose was lowered 3.5 times more than after glibenclamide (HB 419) and after intravenous administration, 2.5 times more. The more rapid decrease in blood glucose in the dog after oral administration of glimepiride was accompanied by a correspondingly earlier and higher plasma insulin increase^[3]. Glimepiride is a second-generation sulfonylurea that stimulates pancreatic β cells to release insulin. It can also be combined with other antihyperglycemic agents, including metformin and insulin, in patients who are not adequately controlled by sulfonylureas alone^[4]. Glimepiride decreased extracellular Aβ40 and Aβ42 levels. The effect of glimepiride on reduction of Aβ40 generation was mediated by downregulation of β-site APP-cleaving enzyme 1 (BACE1) mRNA and protein expression, and by suppression of BACE1 activity^[5].